Skip to main content

Table 3 Dose reduction level

From: Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study

  Docetaxel Oxaliplatin S-1
Level 0 40 mg/m2 100 mg/m2 120 mg/body 100 mg/body 80 mg/body
Level − 1 35 mg/m2 85 mg/m2 100 mg/body 80 mg/body 65 mg/body
Level − 2 30 mg/m2 70 mg/m2 80 mg/body 65 mg/body 50 mg/body